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Abstract 
Background: Epstein-Barr virus and Cytomegalovirus reactivations frequently occur after allogeneic stem cell trans-
plantation (SCT).
Methods: Here we investigated the role of immune cell reconstitution in the onset and subsequent severity of EBV- 
and CMV-reactivation. To this end, 116 patients were prospectively sampled for absolute T cell (CD4 and CD8), B-cell 
(CD19) and NK-cell (CD16 and CD56) numbers weekly post-SCT during the first 3 months and thereafter monthly until 
6 months post-SCT. Viral load was monitored in parallel.
Results: In contrast to the general belief, we found that early T-cell reconstitution does not play a role in the onset of 
viral reactivation. CMV reactivation in the first 7 weeks after SCT however resulted in higher absolute CD8+ T-cell num-
bers 6 months post-SCT in patients with high-level reactivation, many of which were CMV-specific. Interestingly, rapid 
reconstitution of CD4+ T-cells, as well as NK cells and the presence of donor KIR3DL1, are associated with the absence 
of CMV-reactivation after SCT, suggestive of a protective role of these cells. In contrast, EBV-reactivations were not 
affected in any way by the level of immune reconstitution after SCT.
Conclusion: In conclusion, these data suggest that CD4+ T-cells and NK cells, rather than CD8+ T-cells, are associated 
with protection against CMV-reactivation.
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Background
Herpesvirus reactivations, both Epstein-Barr virus (EBV) 
[1] and Cytomegalovirus (CMV) [2, 3], occur frequently 
after allogeneic hematopoietic stem cell transplantation 
(SCT). Both viruses persist lifelong in the host in whom 
there is a tightly regulated balance between the virus 
infected cells and control by cytotoxic T-cell responses 
[1, 4, 5]. However, during the immunosuppressive state 
following SCT, viral reactivation can cause severe com-
plications. Early diagnosis and treatment is considered 
crucial in order to prevent EBV-associated post-trans-
plant lymphoproliferative disorders (EBV-PTLD) and 
CMV disease related mortality after SCT [6].
Frequent monitoring of EBV and CMV-DNA loads 
post transplantation is used to detect viral reactivations 
and infections providing a basis for pre-emptive ther-
apy to prevent clinical complications [7, 8]. Both CD8+ 
T-cells as well as Natural Killer (NK) cells are key effec-
tor cells in eliminating virus-infected cells [9, 10]. For 
EBV it has been shown that incorporating T-cell recon-
stitution data increases the positive predictive value 
for development of EBV-PTLD [11]. Also for CMV, 
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10 × 106/l were shown to be associated with protection 
from CMV-disease [12]. As measuring antigen-specific 
T-cell responses is often elaborate and patient-specific 
reagents are needed, a more general measure for immune 
reconstitution, including absolute cell counts, would 
be favored. In this light, Annels et  al. have indicated an 
arbitrary value of sufficient T-cell reconstitution for 
which pre-emptive therapy can be withheld upon EBV-
reactivation [13]. However, insufficient data exist on the 
relationship between viral reactivations and immune 
reconstitution. Even more, no comparative data exists on 
the role of different viruses on immune reconstitution in 
a single study.
Therefore, we here investigated the relationship 
between immune reconstitution and viral reactivation 
for both EBV and CMV separately in a prospective study 
in 116 allogeneic SCT recipients. We measured absolute 
CD4+ and CD8+ T-cells, CD16+ and CD56+ NK cells, 
and CD19+ B-cells weekly during the first 12 weeks post-
SCT and thereafter at a monthly basis. We show that 
presence of donor inhibitory killer cell immunoglobu-
lin-like receptor (KIR) KIR3DL1, rapid reconstitution of 
CD4+ T-cells and NK cells early after SCT is protective 
against CMV reactivation. In contrast, CMV reactiva-
tion early after SCT results in an enormous increase in 
total CD8+ T-cells 6  months post-SCT, many of which 
are CMV-specific. We did not observe any link between 
immune reconstitution dynamics and EBV reactivations 
in our cohort.
Methods
Study population and study design
116 patients receiving allogeneic SCT between January 
2007 and June 2009 were prospectively followed during 
6  months post-SCT at the department of Haematology 
of the University Medical Center Utrecht. Blood samples 
were drawn weekly from all patients to determine EBV 
and CMV load. After removal of plasma for EBV and 
CMV PCR analyses, the leftover whole blood was used in 
this study. The research was approved by the UMCU eth-
ics committee. Written informed consent was obtained 
from all patients and studies were conducted in accord-
ance with the guidelines of the World Medical Associa-
tion’s Declaration of Helsinki.
CMV and EBV‑monitoring
CMV and EBV-monitoring was based on real-time 
TaqManTM CMV or EBV DNA PCR assay in ethyl-
enediaminetetra acetic acid (EDTA)-plasma [14–16] 
performed weekly in all patients until 4  months post-
transplantation. Patients were treated pre-emptively with 
valganciclovir (900 mg twice daily) when CMV-DNA load 
exceeded 500 copies/ml and with Rituximab 375 mg/m2 
when EBV-DNA exceeded 1000 copies/ml. Valaciclovir 
prophylaxis was given to all patients (500 mg twice daily). 
Viral reactivations and/or infections were defined as EBV 
and or CMV viral load exceeding the detection limit of 
50 copies/ml in plasma.
Absolute immune cell counts
To determine the absolute number of immune cells per 
µl whole blood, TRUcount™ tubes (BD Biosciences (BD), 
San José, California, USA) were used according to man-
ufacturers’ protocol. In brief, 50  µl of whole blood was 
incubated with CD45-PerCP (BD), CD3-Pacific Blue 
(eBioscience Inc., San Diego, California, USA), CD8-
APC-Cy7 (BD), CD4-PE-Cy7, CD16-PE, CD19-FITC 
and CD56-APC. Thereafter erythrocytes were lysed (BD 
lysisbuffer) and samples were measured on LSR-II FACS 
machine. At least 2000 lymphocytes were measured 
(identified as CD45+SSClow) and analyzed with FACSdiva 
software (BD). We gated on CD3+CD4+ T-lymphocytes, 
CD3+CD8+ T-lymphocytes, CD3−CD16+ NK cells, 
CD3−CD56+ NK cells, and CD19+ B cells.
Statistical analysis
All transplantation related risk factors for the develop-
ment of CMV- or EBV-reactivation were assessed using 
a Fisher’s Exact test. We investigated the effects of CMV/
EBV-reactivation on immune reconstitution using piece-
wise linear mixed models. For all subsets, two slopes were 
considered: one for early changes and one for the long-
term trend. The time for the slope’s change (t = 7 weeks) 
was determined for all patients by a likelihood profile. 
The correlation between individual baseline values and 
the subsequent slopes was handled through the unstruc-
tured covariance matrix of random effects. Models were 
adjusted for age at SCT (<50 and  ≥50  years), gender 
and ATG administration. The effects of immune recon-
stitution on CMV/EBV-reactivation were studied with 
Cox proportional-hazards models using time-dependent 
covariates (taking into account the marker changes over 
time). Cumulative incidence of viral reactivation were 
estimated by Kaplan–Meier analysis and were compared 
using the log-rank test.
P  <  0.05 were considered statistically significant. All 
statistical analyses were conducted using SAS version 9.2 
(SAS Institute, Cary, North Carolina, USA) and SPSS ver-
sion 20.0.0 (SPSS Inc, Chicago, Illinois, USA).
Results
Patient population
116 patients receiving allogeneic stem cell transplantation 
between January 2007 and June 2009 were prospectively 
followed during the first 6  months post-SCT for EBV- 
and/or CMV-infections or reactivations. Patient and 
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transplantation related characteristics are described in 
Table 1. Patients received an allogeneic SCT from either 
a related (n =  35) or an unrelated (n =  81) donor. The 
stem cell source was mostly peripheral blood (n =  106) 
and in most patients a nonmyeloablative condition-
ing regime was used (n =  106). In vivo T-cell depletion 
with anti-thymocyte globulin (ATG) was added to the 
conditioning regimen in patients receiving grafts from 
unrelated donors or HLA mismatched donors (n = 87). 
Transplantation associated risk factors that could influ-
ence the onset of viral reactivation were assessed in 
univariate analysis (Table  1). Only CMV serostatus of 
patient and donor (p < 0.0001) and ATG administration 
(p = 0.03) were significantly associated with onset of viral 
reactivation. Figure 1 shows the reconstitution dynamics 
after SCT of median CD4+ and CD8+ T-cells (Fig.  1a), 
B-cells and NK cells (Fig. 1b) for all patients. All subsets 
except CD4+ T-cells reached lower normal levels within 
6 months post-SCT. NK cells reconstituted fastest, within 
5 weeks after SCT their levels reached normal values and 
stabilized. CD4+ and CD8+ T-cells reconstituted simi-
larly, though CD4 levels remained below normal. B-cells 
reconstituted more gradual and reached near normal lev-
els at the end of follow-up.
Viral reactivation
Patients were monitored during 6 months post-SCT for 
both EBV and CMV DNA in plasma. Viral infection or 
reactivation (viral load exceeding 50  copies/ml plasma) 
was diagnosed in 54 patients (47  %, Table  1). Twenty-
eight patients (52 %) developed a low-level (load < 1000 
copies/ml) viral reactivation and 26 (48  %, Table  1) a 
high-level (maximum load >1000 copies/ml). The median 
time to EBV-reactivation was 6 weeks (range 3–56) while 
it was 5 weeks for CMV reactivation (range 1–36 weeks). 
Among the CMV-reactivations, more than two-third 
(68  %) occurred during the first 7  weeks post-SCT. We 
observed two primary CMV infections who did not differ 
in term of time of viral infection and immune reconstitu-
tion from the rest of the patients.
Increased CD8+ T‑cell reconstitution after viral reactivation
To investigate whether the onset of viral reactivation 
after SCT influences the level of immune reconstitu-
tion, we used linear mixed effects models categorizing 
patients based on the occurrence of either EBV- or CMV-
reactivation. No significant differences were observed in 
CD4+ T-cell and CD19+ B-cell reconstitution during the 
first 6 months post-SCT between patients with or with-
out CMV-reactivation (Fig.  2). Remarkably, as reported 
recently by us for a retrospective cohort [17], the level 
of CD8+ T-cells 3–6 months post-SCT was significantly 
higher in patients with a CMV-reactivation compared 
to patients without in this larger prospective study 
(p  <  0.0001). Moreover, patients with a CMV-reactiva-
tion showed a significantly lower level of NK cells (both 
CD16 and CD56) during the first months post-SCT com-
pared to patients without CMV-reactivation (p =  0.007 
and p  =  0.018 respectively), which was independent 
of age, gender and ATG administration. Interestingly, 
when categorizing patients based on the occurrence of 
EBV instead of CMV-reactivation, no differences were 
observed in reconstitution dynamics for any of the cell 
types (Fig. 3).
Patients with CMV-reactivation showed significantly 
higher numbers of CD8+ T-cells at 6  months post-SCT 
(median 567, range 50–3589 CD8+ T-cells/µl) compared 
to patients without (median 188, range 12-713 CD8+ 
T-cells/µl; p  <  0.0001). Our current prospective cohort 
with dense and extensive measurements allowed us to 
investigate if these high numbers were driven by the level 
and/or timing of CMV-reactivation. The highest num-
bers of CD8+ T-cells at 6 months post-SCT occurred in 
patients with a high-level CMV-reactivation (median 
1419, range 295–3589 CD8+ T-cells/µl) (Additional 
file 1: Figure S1) and were threefold higher compared to 
healthy controls (average CD8+ T-cell number in healthy 
controls 395 cells/µl). Moreover, we found that patients 
with a CMV-reactivation during the first seven weeks 
post-SCT had higher CD8+ T-cell counts at 6  months 
post-SCT compared to patients with later CMV-reacti-
vation (p < 0.0001). These data suggest that the observed 
increase in CD8+ T-cell numbers was the result of CMV-
reactivation rather than playing a role in protection 
against CMV-reactivation. In contrast, EBV-reactivation 
seemed to play no role in CD8+ T-cell reconstitution.
The level of CD4+ and CD16+ cells has prognostic value 
for the risk of CMV‑reactivation
As we observed that NK cell levels during the first weeks 
post-SCT were higher in patients without CMV-reactiva-
tion, we used Cox proportional hazard models to inves-
tigate if the level of NK cells could be a predictor of the 
occurrence of subsequent CMV-reactivation. Indeed, 
with each increase of 50 CD16+ cells/μl, the risk of an 
early CMV-reactivation decreased with 20 % (HR: 0.800; 
95 % CI [0.664; 0.963], Table 2). Interestingly, also a suffi-
cient number of CD4+ T-cells was found to be associated 
with lower risk of CMV-reactivation: with each increase 
of 100 CD4+ T-cells/μl the risk of CMV-reactivation 
decreased with ~20 % (HR: 0.837; 95 % CI [0.704; 0.994], 
Table  2). No significant associations were found for the 
other subsets (Table 2).
On average, CMV-reactivation occurred around 
5  weeks post-SCT. Therefore, we next investigated 
whether CMV-reactivation occurs less frequently in 
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patients with CD4+ T-cells and/or CD16+ NK cells above 
the median value observed at week 5 post-SCT. Indeed, 
the cumulative incidence (CI) of CMV-reactivation was 
significantly lower in patients with an absolute CD4+ 
T-cell count above 55 cells/μl (p = 0.019, Fig. 4a). Simi-
larly, patients with a CD16+ cell count above 84 cells/
μl had a significantly lower risk of CMV-reactivation 
(p = 0.0014; Fig. 4b).
Finally, we analyzed the impact of CMV-reactiva-
tion on the time to normalize cell counts. In line with 
our previous data we observed that patients with a 
CMV-reactivation tend to reach the lower bound of 
normal CD8+ T-cell counts faster compared with 
patients without a CMV-reactivation (p  =  0.13, data 
not shown). On the other hand, patients with a CMV-
reactivation tend to reach the lower bound of normal 
Table 1 Patient characteristics
ATG anti-thymocyte globulin; EBV Epstein-Barr virus; CMV cytomegalovirus; R/D recipient/donor; aGVHD acute graft versus host disease; NA non-applicable
a Comparison between reactivation and no reactivation group: unpaired t test for age, univariate analysis using Fisher’s Exact test
b Patients were categorized in reactivation categories based on their peak viral load of either EBV and/or CMV DNA in plasma during 6 months post-SCT
Total Reactivation p valuea
Total (%) CMV only EBV only CMV and EBV
Number of patients 116 54 (47) 36 9 9
Sex
 M 71 30 (42) 18 8 4 0.26
 F 45 24 (53) 18 1 5
Median age (range) 49.8 (17.6–70.6) 50.7 (17.6–68.5) 55.7 (28.5–68.5) 55.8 (17.5–68.3) 56.8 (23.8–65.8) 0.43
Stemcell source
 Cord blood 1 0 (0) 0 0 0 0.30
 Peripheral blood 106 48 (45) 34 6 7
 Bone marrow 9 6 (67) 2 3 2
Donor
 Related 35 13 (37) 11 1 2 0.23
 Unrelated 81 40 (5) 25 8 7
 HLA mismatch 20 11 (55) 7 2 2
Conditioning
 NMA 106 50 (47) 36 6 8 0.47
 MA 10 4 (40) 0 2 2
 ATG 87 46 (53) 28 9 9 0.03
EBV serology (R/D)
 +/+ 94 42 (45) 27 8 7 0.84
 +/− 5 3 (60) 1 0 2
 −/+ 4 2 (50) 2 0 0
 −/− 11 6 (54) 5 1 0
CMV serology (R/D)
 +/+ 39 28 (72) 24 0 4 <10−4
 +/− 37 18 (49) 10 5 3
 −/+ 10 2 (20) 1 0 1
 −/− 28 5 (18) 1 4 0
aGVHD
 Yes 64 29 (44) 17 5 7 0.83
 No information 19 9 (47) 8 1 0
 Relapse 14 7 (50) 2 0 0 0.78
Viral loadb
 Low (<1000 copies/ml) NA 28 (52) 21 4 3 NA
 High (>1000 copies/ml) NA 26 (48) 15 5 6
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NK cell counts slower compared with patients with-
out a CMV-reactivation (p  =  0.13 and p  =  0.05 for 
CD16+ and CD56+ respectively, data not shown). Even 
though a higher than median value of CD4+ T-cells 
5 weeks post-SCT was associated with a lower risk of 
CMV-reactivation, almost none of the patients reached 
the lower bound of normal CD4+ T-cells during fol-
low-up. Again, no difference was observed in time to 
normalize B-cells between patients with or without a 
CMV-reactivation.
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Fig. 1 Reconstitution dynamics for the whole patient population. Absolute cell counts were determined weekly during the first 12 weeks and 
thereafter at a monthly basis. In (a) the median value for CD4+ and CD8+ T cells are plotted per time point. Lower normal values for healthy con-
trols, based on Jentsch-Ullrich et al. (Clin Immunol 2005) and Comans-Bitter et al. (J Pediatr 1997), are depicted with a dashed line. Similarly, in (b) the 
median value for CD16+ and CD56+ NK cells, as well as CD19+ B cells are plotted per time point
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Fig. 2 Longitudinal analysis of immune reconstitution dynamics for patients with or without CMV reactivation. Patients were subdivided based 
on whether or not they experienced CMV reactivation(s), based on CMV viral load exceeding the detection limit of 50 copies/ml in plasma. Data 
were analyses using piecewise linear mixed models with a two slope model. Reconstitution dynamics of CD4+ T cells, CD8+ T cells, CD16+ NK cells, 
CD56+ NK cells and CD19+ B cells are plotted per group. Grey squares depict the median value per time point for patients without CMV reactivation, 
black triangles depict the median value per time point for patients with CMV reactivation
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Genetic presence of donor inhibitory KIR 3DL1 is 
associated with a lower risk of CMV‑reactivation
Both T and NK cells express killer cell immunoglobulin-
like receptors (KIR) which bind to HLA molecules and 
can deliver inhibitory or activating signal to cells [18]. 
As patients at high risk of infection can be identified by 
genotyping KIRs, we next investigated if donor KIRs 
have a protective effect on CMV-reactivation. We found 
that patients with donor KIR of haplotype A (no other 
activating KIR than 2DS4) had a lower risk of CMV-
reactivation than patients with donor KIR haplotype B 
(presence of activating KIR other than 2DS4) [HR: 0.427; 
95 % CI (0.255; 0.885)]. We also found that the presence 
of the inhibitory KIR 3DL1 (n = 96) significantly reduced 
the risk of CMV-reactivation of ~80 % (HR: 0.243; 95 % 
CI [0.085; 0.691], Fig. 4c) while the KIR 3DS1 (n = 39), 
a common allelic variation of 3DL1, was not associated 
with CMV-reactivation. Moreover, the activating KIRs 
2DS4 (n  =  54), 2DS2 (n  =  4) and their coexpression 
(n  =  39) were not significantly associated with CMV-
reactivation in our cohort.
Discussion
Persistent viruses, like EBV and CMV, are normally con-
trolled through cytotoxic T-cell responses [1, 4, 5]. Ade-
quate T-cell reconstitution after SCT is therefore crucial 
in preventing viral reactivation progressing to severe com-
plications [11, 12]. Here, we studied the role of immune 
reconstitution in the onset and severity of the viral reac-
tivation. In contrast to the general belief, we found that 
early CD8+ T-cell reconstitution does not play a role in 
the early onset of viral reactivations. Proper reconstitu-
tion of CD4+ T-cells, as well as NK cells, and the presence 
of donor inhibitory KIR 3DL1, however significantly asso-
ciated with a lower risk of CMV-reactivation after SCT.
CD4+ T-cell counts did not return to normal lev-
els during follow-up, as also observed by others [19, 
20]. In addition, we did not find a difference in CD4+ 
T-cell reconstitution between patients experiencing 
CD4







































































Fig. 3 Longitudinal analysis of immune reconstitution dynamics for patients with or without EBV reactivation. Patients were subdivided based on 
whether or not they experienced EBV reactivation(s), based on EBV viral load exceeding the detection limit of 50 copies/ml in plasma. Data were 
analyses using piecewise linear mixed models with a two slope model. Reconstitution dynamics of CD4+ T cells, CD8+ T cells, CD16+ NK cells, 
CD56+ NK cells and CD19+ B cells are plotted per group. Grey squares depict the median value per time point for patients without EBV reactivation, 
black triangles depict the median value per time point for patients with EBV reactivation
Table 2 Cox proportional hazard analysis of  the effect 
of reconstitution after SCT on the risk of CMV reactivation
Increase of Hazard ratio [95 % CI] p value
CD4 100 cells 0.837 [0.704;0.994] 0.04
CD8 100 cells 0.982 [0.957;1.007] 0.16
CD16 50 cells 0.800 [0.664;0.963] 0.02
CD56 50 cells 0.877 [0.727;1.058] 0.17
CD19 25 cells 0.996 [0.984;1.009] 0.57
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CMV-reactivation or not. We did however find a clear 
association between CD4+ T-cell reconstitution lev-
els early after SCT and the risk of CMV-reactivation. 
The importance of proper CD4+ T-cell reconstitution 
and improved outcome after transplantation has been 
recently emphasized in a pediatric cohort, although this 
study did not investigate the role of CMV [21]. We also 
found that CD4+ T-cells tend to reconstitute better after 
CMV-reactivation in patients with early reactivation (not 
shown). These results suggest that patients with proper 
CD4+ T-cell reconstitution will have a lower risk of 
CMV-reactivation. However, if they do reactivate CMV, 
their CD4+ T-cell counts will increase and reach similar 
levels compared to patients without CMV-reactivation. 
In line with this, Berger et  al. also showed that patients 
with low CD4+ T-cell count on day 35 post-SCT had a 
higher risk of dying of infections [19]. Even though our 
study was not designed to determine an actual cutoff 
value for CD4+ T-cells, nor for NK cells, to be protective 
against CMV-reactivation, we show that a patient with 
e.g. 100  NK cells/μl has a 20  % lower risk to reactivate 
CMV compared with a patient with only 50 NK cells/μl at 
that same moment.
The presence of donor activating KIRs has been 
described to protect against CMV-reactivation in solid 
organ and hematopoietic cell transplantation [22–25]. 
In our study, however, we did not find a protective effect 
of any donor activating KIRs (including KIR 2DS4 and 
2DS2). It is described that the protective effect of KIRs 
might depend on their gene expression levels. Elevated 
KIR gene expression has been shown to be associated 
with risk of CMV-reactivation. These elevated activating 
KIR expressions in CMV-viremic SCT patients might be 
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Fig. 4 Cumulative incidence of CMV reactivation according to CD4+ and CD16+ reconstitution levels and presence of donor KIR 3DL1. a Patients 
were subdivided based on their CD4+ T cell count 5 weeks post-SCT. The cumulative incidence (CI) of CMV reactivation was plotted for patients 
with a CD4+ T cell count below or above the median value of 55 cells/μl. Similarly, in (b) patients were subdivided based on their CD16+ cell count 
5 weeks post-SCT. The median value for the whole patient population was 84 cells/μl. c Patients were subdivided by the presence or not of donor 
inhibitory KIR 3DL1. CI of viral reactivation curves were estimated by Kaplan–Meier analysis and the comparison between the curves of the different 
groups was evaluated by the log-rank test
Page 8 of 9Drylewicz et al. J Transl Med  (2016) 14:230 
CMV [26]. Interestingly, we found that donor KIR 3DL1 
was associated with a lower risk of CMV-reactivation 
supporting a recent study that showed that in vitro 3DL1 
expression correlated with lysis of CMV-infected fibro-
blasts [27]. Moreover, we found that patients with donor 
KIR haplotype A had a lower risk of CMV-reactivation 
than patients with donor KIR haplotype B. Although this 
result is in contradiction with published studies [23, 28], 
a recent study in renal transplant patients also showed 
that depending on HLA-type, KIR haplotype A might be 
protective against infection such as CMV [24].
It is well known that CMV-specific CD8+ T-cells are 
important in the control of CMV-reactivations after 
SCT. However, NK cells were shown to effectively con-
trol CMV infection even in the absence of T-cells [10]. 
We have previously reported the importance of gdT-cells 
after SCT to help resolving viral reactivation [17] (meas-
ured in a subgroup of the present study population) and it 
is therefore tempting to speculate that NK cells, together 
with CD4+ T-cells, are important for the initial control 
of CMV shortly after SCT, whereas CD8+ T-cells as well 
as gdT-cells, are most likely more important for the res-
olution of as well as toxicities due to viral reactivations. 
Several studies have indeed described the association 
between virus-specific T-cells and CMV or EBV-related 
complications [11–13, 29].
In our study we show a strong impact of CMV-reac-
tivation on the number of total CD8+ T-cells following 
reactivation (at 6 months post-SCT). This could result in 
a false positive perception of adequate T-cell reconstitu-
tion. Although high numbers of T-cells are present, these 
are more often of an effector rather than a memory phe-
notype and contain many CMV-specific T-cells (data not 
shown and [30]). This may result in a restricted repertoire 
of the T-cell pool, which may be detrimental for the host. 
Indeed, Suessmuth et  al. recently showed that CMV-
reactivation results in a clonal expansion of CMV-specific 
T-cells and significant defects in the total CD8 Tem TCR 
repertoire [30]. Surprisingly, there were marked differ-
ences in reconstitution dynamics between patients with 
EBV- versus CMV-reactivation. The rapid expansion of 
T-cells seen in patients after CMV-reactivation was not 
observed in patients with high-level EBV-reactivations, 
suggesting that this rapid expansion is not a phenomenon 
caused by viruses in general but is CMV-specific.
In-vivo T-cell depletion through alemtuzumab has 
been shown to delay both CD4+ and CD8+ T-cell recon-
stitution and ATG administration results in a delayed 
CD4+ T-cell reconstitution [31]. Also in our study, we 
observed differences in T-cell counts early after SCT 
between patients who received ATG and patients that did 
not. Treatment with ATG resulted in delayed CD4 recon-
stitution, but increased CD8 T-cell numbers, irrespective 
of viral reactivation (data not shown). Although age is 
also known to have an impact on immune reconstitution 
[32–34], the associations between reconstitution dynam-
ics and viral reactivation we observed here were also 
independent of recipients’ age.
Conclusions
Based on these findings, we hypothesize that onset of 
CMV-reactivation is not influenced by a lack of CD8+ 
T-cell control, but rather by lack of sufficient numbers of 
CD4+ T-cells as well as NK cells early after SCT. CD8+ 
T-cells, on the other hand, significantly increase later 
after CMV-reactivation when most viral reactivations 
had resolved, and thus most likely play an important role 
in determining the outcome of reactivation in the long 
run. Moreover, the marked differences between EBV- and 
CMV-reactivation observed in this study calls for future 
studies investigating potential associations between other 
common viruses and immune reconstitution dynamics 
after SCT.
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